The nasal drug delivery route has distinct advantages, such as high bioavailability, a rapid therapeutic effect, non-invasiveness, and ease of administration. This article presents the results of a study of the processes for obtaining chitosan aerogel particles that are promising as nasal or inhalation drug delivery systems. Obtaining chitosan aerogel particles includes the following steps: the preparation of a chitosan solution, gelation, solvent replacement, and supercritical drying. Particles of chitosan gels were obtained by spraying and homogenization. The produced chitosan aerogel particles had specific surface areas of up to 254 m2/g, pore volumes of up to 1.53 cm3/g, and porosities of up to 99%. The aerodynamic diameters of the obtained chitosan aerogel particles were calculated, the values of which ranged from 13 to 59 µm. According to the calculation results, a CS1 sample was used as a matrix for obtaining the pharmaceutical composition “chitosan aerogel—clomipramine”. X-ray diffraction (XRD) analysis of the pharmaceutical composition determined the presence of clomipramine, predominantly in an amorphous form. Analysis of the high-performance liquid chromatography (HPLC) data showed that the mass loading of clomipramine was 35%. Experiments in vivo demonstrated the effectiveness of the pharmaceutical composition “chitosan aerogel—clomipramine” as carrier matrices for the targeted delivery of clomipramine by the “Nose-to-brain” mechanism of nasal administration. The maximum concentration of clomipramine in the frontal cortex and hippocampus was reached 30 min after administration.
1 December 2023 in Russian Journal of Physical Chemistry B
Protein (eggwhite) and chitosan aerogel microparticles characterized by low density, developed morphology, high specific surface area, high porosity, large volume, and small pore diameter, have been obtained. Particle size distribution curves were obtained by laser diffraction, from which the number average and aerodynamic diameters were calculated. The aerodynamic diameter of all of the obtained biopolymer aerogels lies in the range required for targeted delivery of active pharmaceutical ingredients (APIs) to the olfactory region of the nasal cavity. Experimental studies were performed to introduce the “melatonin” API in the pores of biopolymer aerogels at the solvent replacement and supercritical adsorption steps. The mass fractions of APIs in the resulting biopolymer aerogel–API pharmaceutical composites were determined by high-performance liquid chromatography. An X-ray powder diffraction analysis showed that API was present in pharmaceutical compositions mainly in the amorphous state. The results of in vivo experimental studies showed that in the case of intranasal administration of both biopolymer aerogel–API composites, the maximum concentration of API in brain tissues is reached already after 30 min. This proves that the obtained biopolymer aerogels based on protein (eggwhite) and chitosan are promising for use as API carrier matrices in the development of nasal drug delivery systems.
In this work, active pharmaceutical ingredients release from aerogel particles and active pharmaceutical ingredients transportation processes were investigated. Experimental studies were carried out on the release of various types of active pharmaceutical ingredients from various types of aerogel particles. Release curves were obtained. A hybrid model using the lattice Boltzmann method and a cellular automata approach to simulate the release of active pharmaceutical ingredients from aerogel particles and active pharmaceutical ingredients transport processes is proposed. The proposed model can be used in new drug development, which allows partially replacing full-scale experiments with computational ones, therefore reducing the experimental studies cost.
An information-analytical software has been developed for creating digital models of structures of porous materials. The information-analytical software allows you to select a model that accurately reproduces structures of porous materials—aerogels—creating a digital model by which you can predict their properties. In addition, the software contains models for calculating various properties of aerogels based on their structure, such as pore size distribution and mechanical properties. Models have been implemented that allow the description of various processes in porous structures—hydrodynamics of multicomponent systems, heat and mass transfer processes, dissolution, sorption and desorption. With the models implemented in this software, various digital models for different types of aerogels can be developed. As a comparison parameter, pore size distribution is chosen. Deviation of the calculated pore size distribution curves from the experimental ones does not exceed 15%, which indicates that the obtained digital model corresponds to the experimental sample. The software contains both the existing models that are used for porous structures modeling and the original models that were developed for different studied aerogels and processes, such as the dissolution of active pharmaceutical ingredients and mass transportation in porous media.
20 December 2025 in Problems of Biological, Medical and Pharmaceutical Chemistry
Introduction. Vinpocetine has neuroprotective properties and is used to improve cognitive function; however, poor solubility and low bioavailability may limit its use. The development of a dry nasal spray vinpocetine with increased solubility is a topical issue. Aim of the study was to develop the composition of a prototype dry nasal spray of vinpocetine and the technology for its production. Material and Methods. The prototypes contained chitosan and synthesized poly-β-cyclodextrin. The formation of host-guest inclusion complexes by co-dissolution and co-attrition methods increased vinpocetine solubility. IR spectroscopy and X-ray diffraction analysis were used to confirm the formation of inclusion complexes and evaluate the sample properties. Spray drying was the final step in the formation of the dry nasal spray. The stability and mass (volume) uniformity of doses taken from a multi-dose package, dosing in a dry powder dispenser, and in vitro permeability in a transdermal diffusion tester were studied for the lead formulation. Results. Comparative studies of the developed samples with different vinpocetine:polycyclodextrin ratios were conducted. No significant differences in inclusion complex formation were demonstrated by the two methods. Therefore, the co-dissolution method was chosen as the preferred method for producing dry nasal spray prototype samples, as it is technologically simpler. In vitro permeation results showed that most of the vinpocetine dissolves and penetrates the membrane within 30 minutes. Dosage uniformity and stability of the developed prototypes for 12 months were demonstrated. Conclusions. The experimental studies demonstrate the feasibility of using powder particles containing the vinpocetine-polycyclodextrin inclusion complex and chitosan, obtained by spray drying, as prototypes for a dry nasal spray for vinpocetine.
30 June 2026 in Proceedings of the Voronezh State University of Engineering Technologies
Molnupiravir is an antiviral drug used to treat the novel coronavirus infection, COVID-19, caused by the SARS-CoV-2 virus. Currently, it is available only in oral form. Developing an alternative inhalation dosage form could increase the drug's bioavailability through targeted action on the organs most affected by the infection, while simultaneously reducing the dosage of the active ingredient and minimizing the risk of systemic side effects. The aim of this study is to evaluate the influence of L-leucine and lactose monohydrate on the particle size distribution and key aerodynamic characteristics of the resulting inhalation powder prototypes, and to select the leading formulation for the current development stage. Spray drying was chosen as the primary technology for obtaining the samples. The paper presents a spray-drying technique that ensures the necessary dispersion and uniformity of the product. Following this method, two samples were prepared containing a model substance and excipients (Sample 1: Poloxamer 188 and Hypromellose; Sample 2: Poloxamer 188, Hypromellose, and L-leucine). Additionally, a portion of Sample 1 underwent mechanical blending with a carrier (lactose monohydrate). The particle size distribution of the powder compositions was studied using an optical microscope (granulometric analysis) and a Next Generation Cascade Impactor (aerodynamic characterization). The effects of the amino acid (L-leucine) and the carrier (lactose monohydrate) on the formulation characteristics were evaluated. Based on the comparative analysis, an intermediate leading formulation was selected (Sample 1 with the addition of lactose monohydrate), and a plan for further development was established (incorporating lactose monohydrate at various weight percentages and exploring a combination of leucine and lactose monohydrate).